The goal of this clinical trial is to demonstrate the effectiveness of non-invasiveNeuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologiesderived from the consequences of Covid-19. It will also estimate the impact ofnon-invasive neuromodulation treatment on the functionality and quality of life ofpatients with COVID-19 sequelae.The main question it aim to answer is: - Is non-invasive neuromodulation effective as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19.Researchers will compare non-invasive neuromodulation to a placebo (treatment with themachine turned off).Participants will: - Be evaluated before starting treatment. - Be evaluated 3 weeks after. - Be evaluated at 5 weeks, or 15 sessions or completion of treatment. - Be evaluated 6 weeks after finishing the treatment or 11 weeks after starting treatment.
The waves of Sars-Cov-2 disease continue to be continuous and we are increasingly aware
of the consequences it causes both in the respiratory system, musculoskeletal system and
in the central and peripheral nervous system.
Likewise, non-invasive neuromodulation acts with a pump of ions, generating endogenous
stimuli that modulate the central nervous system.
The aim of this clinical trial is to demonstrate the effectiveness of non-invasive
Neuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologies
derived from the consequences of Covid-19.
To carry out this study, pain was measured with the visual analogue scale. It was also
measured the joint amplitude, a muscle assessment with the help of a strength
dynamometer, the patient's independence with the Katz index and the functionality of the
lower or upper limbs, depending on the affected joint.
Device: Non invasive neuromodulation therapy
In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.
Each intervention lasted 60 minutes. The intensity will be programmed in all sessions at
Low, following the Arndt-Schulz law. The treatment was distributed in 3 phases: phase 1
of preparation, phase 2 to reduce fatigue and phase 3 to enhance autonomic improvement.
Other: Manual therapy
Common manual therapy administered for said pathology by traditional physiotherapy and
therapeutic exercise.
Device: Placebo with non invasive neuromodulation
In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.
Each intervention lasted 60 minutes. The treatment was carried out with the machine
turned off.
Inclusion Criteria:
- Patients between the ages of 18 and 60.
- Patients with a positive diagnosis of COVID-19.
- Patients with post-COVID-19 sequelae with musculoskeletal, respiratory or
neurological symptoms due to taste or smell lasting at least 30 days, with no
history of respiratory and/or neurological and/or musculoskeletal diseases.
- Patients who signed the informed consent.
Exclusion criteria:
- Patients aged before 18 years and after 60 years.
- Healthy people with no history of neurological, neurological and/or respiratory
and/or musculoskeletal diseases
- Patients with secondary diseases that could directly affect the systems to be
evaluated who were not diagnosed positive for COVID-19.
Gema León Physiotherapy and Rehabilitation Clinic
Córdoba, Andalucía, Spain
GEMA LEÓN BRAVO
+34667401116
gemafisio@gmail.com
GEMA LEÓN BRAVO
+34667401116
gemaleonbravo@icloud.com
GEMA LEÓN BRAVO, Principal Investigator
Departamento de Enfermería, Farmacología y Fisioterapia de la Universidad de Córdoba